1. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse 
Yoo-Jin Kim, Dong-Wook Kim, Seok Lee, Chang-Ki Min, Hyun-Gyung Goh, Su-Hyun Kim, Ji-Young Lee, Yoo-Li Kim, Hee-Je Kim, Hyeoung-Jun Kim, Jong-Wook Lee, Tai-Gyu Kim, Woo-Sung Min, Chun-Choo Kim 
Biology of Blood and Marrow Transplantation 
Volume 10, Issue 10, Pages (October 2004)
DOI: /j.bbmt
Copyright © 2004 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Probability of overall survival according to the best response after imatinib therapy in patients achieving a complete cytogenetic response.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2004 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Kinetics of the normalized BCR-ABL transcript levels in patients achieving a molecular remission (a) or a complete cytogenetic response (b) as a best response to imatinib therapy.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2004 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Probability of molecular remission according to the BCR-ABL transcript levels at 6 months (a) and to the log-reduction of the BCR-ABL transcript levels between 3 and 6 months (b).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2004 American Society for Blood and Marrow Transplantation Terms and Conditions